Bronchitol®

CSP is building an innovative, differentiated and late-stage pipeline of products. Our 1st Rare disease product is for the treatment of Cystic fibrosis.

Bronchitol is approved for the treatment of cystic fibrosis to help patients clear mucus from their lungs. It is a precision spray-dried form of mannitol, delivered to the lungs by a specially designed, portable inhaler. Bronchitol works by rehydrating the airway/lung surface and promoting a productive cough.

Bronchitol was the subject of three large scale clinical trials and is approved in over 30 countries, including the USA, Europe, UK and Australia.

Clinical trials have shown that Bronchitol helps to increase mucus clearance, and improve the lung function and the quality of life of people living with cystic fibrosis.

In China, Bronchitol is now approved in several pilot zones. Cystic fibrosis, which is listed on the Chinese catalogue of rare diseases is a greatly under-recognised condition in China with no approved pharmaceutical products. Bronchitol has been recommended in the China cystic fibrosis diagnosis and treatment guideline.